Latest / The Well-Built Life / Navigating Giant Axonal Neuropathy
Transcript
- 0:00Speaker 1: Hey everyone, welcome back to The Well-Built Life. I am
- 0:03Speaker 1: Rachel Caldwell, alongside Thomas Bennett, and we are so glad
- 0:07Speaker 1: you are tuning in. We are here to cut through
- 0:09Speaker 1: the noise, skip the intense jargon and extreme rules, and
- 0:14Speaker 1: share simple practical habits that help you feel stronger, healthier,
- 0:18Speaker 1: and more balanced every single day. Grab a drink, get comfortable,
- 0:23Speaker 1: and let's dive in. Hi Thomas, I was thinking about
- 0:26Speaker 1: diving straight into giant axonal neuropathy.
- 0:29Speaker 2: GAN.
- 0:30Speaker 1: It's so interesting because it touches on so many layers, genetic, neurological,
- 0:35Speaker 1: and the journey from first signs to diagnosis. What are
- 0:39Speaker 1: your thoughts on where we should start?
- 0:41Speaker 2: Great question, Rachel. Let's begin with the symptoms, as they
- 0:44Speaker 2: are crucial for early detection. GAN is characterized by gradual
- 0:48Speaker 2: and progressive muscle weakness, along with sensory issues like neuropathic
- 0:52Speaker 2: pain and tingling sensations. These symptoms often start in early
- 0:57Speaker 2: childhood and worsen over time. What do you think would
- 1:00Speaker 2: be the best way to illustrate these symptoms to our audience?
- 1:04Speaker 1: I think starting with a concrete case could be effective.
- 1:07Speaker 1: For instance, we could discuss a patient named Lucas, who
- 1:11Speaker 1: was initially diagnosed with a genetic disorder due to weakness
- 1:14Speaker 1: and unusual sensations. This would help readers understand the journey.
- 1:18Speaker 1: How do you see Lucas' initial symptoms manifesting in his
- 1:23Speaker 1: daily life?
- 1:24Speaker 2: That's a fantastic idea. Let's say Lucas is a six-year-old boy.
- 1:30Speaker 2: His parents notice that he starts struggling to keep up
- 1:33Speaker 2: with his peers in physical activities like running and jumping.
- 1:37Speaker 2: By the time he is 10, he has significant difficulty
- 1:40Speaker 2: climbing stairs and holding lightweight objects. His parents also report
- 1:45Speaker 2: that he experiences frequent tingling sensations and sharp, shooting pains,
- 1:50Speaker 2: particularly in his hands and legs. This would highlight the
- 1:53Speaker 2: progressive nature of and the multisymptom involvement.
- 1:56Speaker 1: Yes, that's excellent. The progressive aspect is critical. Now, let's
- 2:02Speaker 1: move to the genetic causes. GAN is caused by mutations
- 2:06Speaker 1: in the GAN gene, which provides instructions for making the
- 2:09Speaker 1: meganeurone protein. This protein is essential for the structure and
- 2:13Speaker 1: function of nerve cells. What steps would you propose to
- 2:17Speaker 1: explain the role of this gene and protein?
- 2:19Speaker 2: We can start with a simplified genetic mechanism. The GAN
- 2:23Speaker 2: gene is located on the X chromosome, making GAN an
- 2:27Speaker 2: X-linked recessive disorder. Mutations in this gene lead to the
- 2:31Speaker 2: production of a defective meganeuron protein. This protein is crucial
- 2:35Speaker 2: for the stability of axons, the long extensions of nerve
- 2:39Speaker 2: cells that transmit signals. When the protein is defective, it
- 2:43Speaker 2: can't properly support the axons, leading to their degeneration over time. Perfect.
- 2:49Speaker 1: Let's break this down further. Can we discuss how the
- 2:52Speaker 1: axonal degeneration process actually happens? Specifically, the biochemical pathways involved
- 2:59Speaker 1: in axonal stability, and how these are disrupted due to
- 3:02Speaker 1: the defective meganeurone protein?
- 3:04Speaker 2: Absolutely. When the meganeurone protein is functioning correctly, it helps
- 3:08Speaker 2: in the formation of a dense outer layer around the
- 3:11Speaker 2: axon called the myelin sheath. This layer insulates the axon
- 3:15Speaker 2: and ensures the efficient transmission of electrical signals. However …
- 3:20Speaker 2: In GAN, the defective protein disrupts this process.
- 3:23Speaker 1: That's a good point. How exactly does the disruption manifest
- 3:26Speaker 1: at the molecular level? Could we delve into the role
- 3:29Speaker 1: of myelin in preventing demyelination and the mechanisms that are compromised?
- 3:34Speaker 2: Sure. The myelin sheath is composed of layers of fatty
- 3:38Speaker 2: material that not only insulate the axon, but also aid
- 3:42Speaker 2: in the rapid transmission of electrical impulses. In GAN, The
- 3:46Speaker 2: defective meganeuron protein fails to maintain the integrity of the
- 3:50Speaker 2: myelin sheath. This leads to demyelination, where the myelin becomes
- 3:55Speaker 2: thin and eventually breaks down. The resulting gaps in the
- 3:58Speaker 2: myelin sheath slow down or block the transmission of signals,
- 4:03Speaker 2: leading to the symptoms observed.
- 4:04Speaker 1: Excellent explanation. Now, let's talk about the diagnostic process. At
- 4:10Speaker 1: what stage do doctors typically suspect GAN and what steps
- 4:13Speaker 1: follow in the diagnostic journey? Often, patients present with neurological
- 4:19Speaker 1: and muscle symptoms, making GAN more difficult to diagnose. Discuss
- 4:23Speaker 1: how genetic testing plays a crucial role.
- 4:27Speaker 2: Typically, doctors suspect GAN when a patient shows early signs
- 4:31Speaker 2: of muscle weakness and sensory issues, especially in conjunction with
- 4:35Speaker 2: a family history of similar symptoms. The diagnostic journey often
- 4:39Speaker 2: includes a thorough neurological examination, followed by nerve conduction studies
- 4:44Speaker 2: and electromyography to assess nerve function. If the symptoms are
- 4:48Speaker 2: consistent with GAN, doctors will consider genetic testing. This step
- 4:53Speaker 2: is crucial as it confirms the presence of a GAN-related
- 4:56Speaker 2: mutation in the X chromosome. How do you think we
- 4:59Speaker 2: can make this process more understandable for our audience?
- 5:03Speaker 1: Genetic testing is indeed vital. Perhaps we can use a
- 5:06Speaker 1: step-by-step guide to explain the process from the initial consultation
- 5:10Speaker 1: to the results. We could highlight the importance of genetic
- 5:13Speaker 1: counseling and the ethical considerations involved, especially for families with
- 5:18Speaker 1: a history of GAN.
- 5:19Speaker 2: Absolutely. We can start with a simplified flowchart. First, the
- 5:24Speaker 2: patient and family undergo a genetic counseling session to discuss
- 5:27Speaker 2: the implications of testing. Then, a blood sample is collected
- 5:31Speaker 2: to screen for the GAN mutation. Results are available within
- 5:35Speaker 2: a few weeks, and if positive, further confirmatory tests may
- 5:39Speaker 2: be required.
- 5:39Speaker 1: That's a clear and concise way to present it. How
- 5:43Speaker 1: do you think we can further engage our audience in
- 5:46Speaker 1: understanding the importance of genetic testing beyond just the diagnosis?
- 5:50Speaker 2: We can discuss case studies or real-life examples where genetic
- 5:54Speaker 2: testing led to better management and more targeted treatments. For
- 5:58Speaker 2: instance … If a child is diagnosed early, parents can
- 6:01Speaker 2: make informed decisions about their child's care, including potential therapies
- 6:06Speaker 2: and lifestyle modifications. Additionally, genetic testing can help rule out
- 6:11Speaker 2: or confirm other similar conditions, which can be crucial for
- 6:14Speaker 2: tailored treatment plans.
- 6:16Speaker 1: Definitely. Including success stories or the impact of early diagnosis
- 6:21Speaker 1: could be very powerful. We should aim to make this
- 6:24Speaker 1: section relatable and inspiring for our audience. emphasizing the importance
- 6:29Speaker 1: of early detection and genetic testing. Sounds like a plan, Thomas.
- 6:33Speaker 2: Agreed, Rachel. Let's ensure we cover all these aspects comprehensively
- 6:38Speaker 2: and make it informative and engaging. We can also add
- 6:42Speaker 2: interactive elements like quizzes or infographics to help summarize the
- 6:46Speaker 2: key points.
- 6:47Speaker 1: So, let's dive into the nitty-gritty. Thomas, you mentioned in
- 6:51Speaker 1: our last segment that GAN initiates at the genetic level
- 6:54Speaker 1: with a deficiency in gigaxonin. Can we start by unpacking
- 6:58Speaker 1: how this directly impacts axonal function?
- 7:01Speaker 2: Absolutely, Rachel. Gigaxonin's role is critical because it acts as
- 7:05Speaker 2: a recycling manager, clearing out old, worn-out structural filaments. Without
- 7:10Speaker 2: sufficient functional gigaxonin, these neurofilaments accumulate, leading to the giant
- 7:15Speaker 2: axons you mentioned. This accumulation disrupts the axonal transport mechanism,
- 7:20Speaker 2: which is absolutely crucial for nerve function.
- 7:23Speaker 1: That's a really clear way to put it. Can you
- 7:26Speaker 1: explain how this disruption actually manifests in daily life for
- 7:30Speaker 1: someone with GAN? I think that will make the mechanism
- 7:32Speaker 1: more relatable to our audience.
- 7:35Speaker 2: Sure. It's all about the disorganization of these neurofilaments. Imagine
- 7:40Speaker 2: a highway of traffic. Normally, everything runs smoothly. But with
- 7:44Speaker 2: the accumulation, it's like cars are getting stuck at every turn.
- 7:48Speaker 2: The axonal transport. which is vital for sending signals, gets
- 7:52Speaker 2: really inefficient. The signals slow down, and that contributes to
- 7:56Speaker 2: the muscle weakness and sensory issues we see, like difficulty
- 7:59Speaker 2: running and frequent falls.
- 8:01Speaker 1: Right, and that's the crucial nuance here. So, when we
- 8:05Speaker 1: talk about current supportive care, what are we actually doing?
- 8:09Speaker 1: Is it enough to manage the symptoms, or are we
- 8:12Speaker 1: just putting a band, aid on a deeper issue?
- 8:15Speaker 2: Great question. Current supportive care involves managing symptoms through physical
- 8:20Speaker 2: and occupational therapy, medications for muscle spasms and seizures, and
- 8:25Speaker 2: speech therapy. It's not a cure-all. It's about maintaining function
- 8:30Speaker 2: and quality of life as symptoms progress. But it doesn't
- 8:33Speaker 2: address the root cause of the axonal dysfunction.
- 8:36Speaker 1: Exactly. Which brings up an interesting contradiction. While supportive care
- 8:41Speaker 1: is essential, gene therapy and regenerative medicine are hold promise
- 8:45Speaker 1: for tackling the root of the issue. What are the
- 8:49Speaker 1: key differences between these approaches? And why are they so exciting?
- 8:53Speaker 2: Gene therapy aims to directly address the genetic defect by
- 8:57Speaker 2: introducing a healthy version of the gone gene into the
- 9:00Speaker 2: patient's cells. Regenerative medicine, on the other hand, tries to
- 9:04Speaker 2: repair or regenerate damaged tissue through various techniques, including stem cells.
- 9:10Speaker 2: The exciting part is that both could potentially halt or
- 9:14Speaker 2: even reverse the accumulation of neurofilaments and the disruptive effects
- 9:18Speaker 2: on axonal transport.
- 9:20Speaker 1: That's wild when you look at the raw numbers. But,
- 9:23Speaker 1: of course, we need to balance that excitement with realistic expectations.
- 9:28Speaker 1: What are the practical challenges and current status of these approaches?
- 9:32Speaker 2: The clinical trials are ongoing, and the preliminary results are promising.
- 9:37Speaker 2: But the field is still very much in its early stages.
- 9:40Speaker 2: Questions remain about the long-term effects, safety, and delivery methods.
- 9:45Speaker 2: The multidisciplinary approach involving geneticists, neurologists, and biomedical researchers is crucial.
- 9:53Speaker 2: We need to ensure that these therapies can be translated
- 9:56Speaker 2: effectively into clinical practice. True.
- 10:00Speaker 1: And as we move forward, patient support and community engagement
- 10:04Speaker 1: will be key. How can we make sure that these
- 10:07Speaker 1: advanced therapies are not just promising, but also accessible to
- 10:12Speaker 1: those who need them?
- 10:13Speaker 2: Agreed. It's about building a comprehensive ecosystem that includes robust funding,
- 10:19Speaker 2: ethical considerations, and patient advocacy. We should also focus on
- 10:23Speaker 2: early diagnosis and genetic testing, as they are game changers
- 10:27Speaker 2: in managing GAN more effectively.
- 10:29Speaker 1: Exactly, and making these tools more widely available and affordable.
- 10:35Speaker 1: I think that's where our role as a podcast can
- 10:38Speaker 1: really help by educating our audience and raising awareness. Any
- 10:42Speaker 1: final thoughts?
- 10:43Speaker 2: Thomas? Just that every step forward in research and clinical
- 10:47Speaker 2: care brings us closer to better understanding and eventually curing GAN.
- 10:52Speaker 2: We owe it to the patients to stay committed and engaged.
- 10:56Speaker 1: So, moving forward, let's delve into the roles of geneticists, neurologists,
- 11:01Speaker 1: and other stakeholders in diagnosing and treating GAN. Thomas, how
- 11:06Speaker 1: does genetic testing fit into this landscape?
- 11:08Speaker 2: Genetic testing is crucial. Rachel, it's now the cornerstone of diagnosis.
- 11:13Speaker 2: Eliminating the need for nerve biopsies and ensuring more accurate
- 11:17Speaker 2: and non-invasive confirmation of GAN, it helps identify those 100%
- 11:22Speaker 2: of patients who have mutations in the GAN gene.
- 11:25Speaker 1: That's right. It simplifies the process and allows for early
- 11:28Speaker 1: detection and intervention. And it's not just about diagnosis, is it?
- 11:33Speaker 1: It has implications for patient management as well.
- 11:36Speaker 2: Absolutely. Once diagnosed, geneticists and neurologists must coordinate care to
- 11:42Speaker 2: manage symptoms effectively. Research shows that 95% of GAN patients
- 11:47Speaker 2: benefit from physical and occupational therapy to maintain their muscle
- 11:51Speaker 2: function and joint mobility.
- 11:53Speaker 1: And what about the prevalence of symptoms? Do we see
- 11:56Speaker 1: much variation in how these issues present?
- 11:58Speaker 2: Precisely. While 100% of patients display muscle weakness, The degree
- 12:03Speaker 2: to which they experience decreased reflexes or sensory abnormalities can
- 12:08Speaker 2: vary widely. The prognosis also varies. 60% might develop scoliosis,
- 12:14Speaker 2: but the lifespan can range broadly, from 7 to 30
- 12:17Speaker 2: years post. Diagnosis, depending on the severity of central nervous
- 12:22Speaker 2: system involvement.
- 12:23Speaker 1: Interesting. It's clear that early intervention is key. How do
- 12:28Speaker 1: neurologists and other specialists contribute to early detection, and management.
- 12:34Speaker 2: Neurologists play a dual role. They diagnose and monitor the
- 12:38Speaker 2: progression of symptoms, and their clinical assessments can guide the
- 12:42Speaker 2: need for and timing of supportive therapies. They work in
- 12:45Speaker 2: tandem with geneticists to provide a comprehensive care plan.
- 12:49Speaker 1: That's a great point. Speaking of diagnostics, how has the
- 12:53Speaker 1: shift from nerve biopsies to genetic testing impacted the field.
- 12:57Speaker 2: The change to non-invasive genetic testing has streamlined the diagnostic process,
- 13:02Speaker 2: reducing the chances of misdiagnosis and alleviating the stress and
- 13:06Speaker 2: risks associated with biopsies. It also allows for a more
- 13:10Speaker 2: holistic view of the genetic landscape, which can be crucial
- 13:13Speaker 2: in understanding the multifaceted nature of GAN.
- 13:16Speaker 1: And what about the role of support organizations in this ecosystem?
- 13:21Speaker 1: How do they contribute? to patient care?
- 13:23Speaker 2: Support organizations are invaluable. They provide resources, advocacy, and community support,
- 13:29Speaker 2: helping patients and families navigate the complexities of GAN through education, counseling,
- 13:35Speaker 2: and by connecting them with networks of other families in
- 13:37Speaker 2: similar situations.
- 13:39Speaker 1: Exactly. And how does all this tie into the broader
- 13:42Speaker 1: research landscape? Are there specific areas where biomedical research is
- 13:47Speaker 1: focusing its efforts?
- 13:49Speaker 2: Biomedical research is heavily invested in gene therapy and regenerative medicine,
- 13:54Speaker 2: looking to address the underlying causes of GAN. Terry's also
- 13:58Speaker 2: a push to identify predictive biomarkers that could better predict
- 14:02Speaker 2: disease progression and response to treatment, potentially enabling more personalized therapies.
- 14:08Speaker 1: That's exciting progress. But with all these advancements, do you
- 14:13Speaker 1: see any lingering challenges in the field?
- 14:15Speaker 2: Absolutely. While gene therapy holds promise, there are still significant
- 14:19Speaker 2: hurdles in its clinical implementation. The variability in disease progression
- 14:24Speaker 2: and the need for multidisciplinary care plans highlight the complexity
- 14:28Speaker 2: of managing GAN from diagnosis to treatment.
- 14:31Speaker 1: Yes, and the long-term efficacy of supportive therapies is another
- 14:35Speaker 1: area of critical investigation. It's a multifaceted challenge with no
- 14:40Speaker 1: simple solutions.
- 14:42Speaker 2: Indeed, Rachel. The journey to a cure or more effective
- 14:45Speaker 2: treatments continues. with each progress step bringing us closer, but
- 14:50Speaker 2: also requiring sustained attention and investment.
- 14:53Speaker 1: So, Thomas, let's talk about the current limitations of treatments
- 14:57Speaker 1: and how we are currently trying to bridge that gap.
- 15:00Speaker 1: From what I understand, Therese quite a lot of variability
- 15:04Speaker 1: in how GAN manifests, and this complicates treatment.
- 15:07Speaker 2: Absolutely, Rachel. The variability is indeed a challenge. Patients can
- 15:12Speaker 2: have very different symptoms and disease progressions, which makes it
- 15:16Speaker 2: hard to develop one-size-fits-all treatment protocols. For example, some patients
- 15:22Speaker 2: might have more severe neurological involvement, while others might experience
- 15:26Speaker 2: more significant issues with muscle stiffness.
- 15:28Speaker 1: Right. And this is where multidisciplinary care becomes so crucial.
- 15:33Speaker 1: It's not just about physical therapy or pharmacology, it's about
- 15:37Speaker 1: addressing the whole person. But let's dig into the ethical
- 15:40Speaker 1: considerations of nerve biopsies next. I have heard some debate
- 15:45Speaker 1: over whether they should be used at all.
- 15:47Speaker 2: Yes, Rachel. Nerve biopsies are historically necessary for diagnosis, but
- 15:52Speaker 2: they are invasive and can have complications. They are also
- 15:56Speaker 2: prone to variability in interpretation, which can lead to misdiagnosis.
- 16:01Speaker 2: The shift to genetic testing has somewhat reduced the need
- 16:04Speaker 2: for these invasive procedures, but they still play a role
- 16:07Speaker 2: in some cases.
- 16:09Speaker 1: Exactly. Which brings up an interesting contradiction. On one hand,
- 16:13Speaker 1: we are moving towards less invasive diagnostics. Yet biopsies are
- 16:17Speaker 1: still considered critical in certain scenarios. It's a tension we
- 16:21Speaker 1: need to address. Speaking of which, gene therapy, the talk
- 16:25Speaker 1: now is really about pushing for that. What do you
- 16:28Speaker 1: think the future looks like for GAN research in this area?
- 16:31Speaker 2: The future trajectory seems quite promising. Gene therapy offers the
- 16:35Speaker 2: potential to directly address the root cause by restoring or
- 16:39Speaker 2: correcting the gigaxonin deficiency. However … there are still many challenges.
- 16:44Speaker 2: For instance, the complex nature of the axonal pathology in
- 16:47Speaker 2: GAN means that we need to understand exactly how gigaxonin
- 16:51Speaker 2: functions and how its deficiency leads to the accumulation of neurofilaments.
- 16:56Speaker 1: Right. And this brings us to the broader stakeholder perspective.
- 17:01Speaker 1: What do you think about the push for gene therapy
- 17:04Speaker 1: coming from various stakeholders? From geneticists to pharmaceutical companies, there
- 17:08Speaker 1: are different angles and priorities.
- 17:10Speaker 2: Well, It's a broad coalition. Geneticists are key because they
- 17:14Speaker 2: are doing the fundamental research to understand the molecular mechanisms.
- 17:19Speaker 2: On the other end, companies are very interested in developing treatments,
- 17:23Speaker 2: seeing a potential market, and then you have the patients
- 17:26Speaker 2: and support organizations pushing for more aggressive interventions that could
- 17:30Speaker 2: halt disease progression.
- 17:31Speaker 1: Wait, but how does that actually play out in practice?
- 17:35Speaker 1: I mean, Therese a lot of talk, but what are
- 17:37Speaker 1: we actually doing to get to that point?
- 17:39Speaker 2: That's a good question. In practice, it's about small but
- 17:43Speaker 2: steady progress. Clinical trials are ongoing, and we are seeing
- 17:47Speaker 2: some promising results. For example, the CRISPR-Cas9 technology is being
- 17:53Speaker 2: explored to deliver therapeutic genes to affected neurons. But it's
- 17:57Speaker 2: not a straightforward process. We need to ensure safety and
- 18:01Speaker 2: effectiveness before wider application.
- 18:03Speaker 1: That is quite an ambitious direction, and it raises a
- 18:07Speaker 1: lot of questions. It's a complex landscape. but with so
- 18:11Speaker 1: many stakeholders working towards common goals, I remain optimistic. It's
- 18:16Speaker 1: clear that a holistic approach is necessary to truly make
- 18:20Speaker 1: a difference in the lives of those with GAN.
- 18:22Speaker 2: Indeed, Rachel. It's an exciting space with a lot of potential,
- 18:27Speaker 2: and we are just scratching the surface. However, the journey
- 18:31Speaker 2: to a cure or more effective treatments requires sustained effort
- 18:35Speaker 2: from everyone involved. It's a marathon, not a sprint.
- 18:38Speaker 1: So, Thomas. As we wrap up our deep dive into
- 18:42Speaker 1: giant axonal neuropathy, GAN, let's focus on the key quotes
- 18:47Speaker 1: and what they tell us about this disorder. Giant axonal
- 18:50Speaker 1: neuropathy is a rare inherited neurodegenerative disorder that damages axons,
- 18:55Speaker 1: the long extensions of nerve cells that carry electrical signals.
- 18:59Speaker 1: Isn't it fascinating how these tiny cellular structures are so
- 19:03Speaker 1: crucial for our overall well-being?
- 19:04Speaker 2: Absolutely, Rachel. And that's why understanding the molecular basis of
- 19:09Speaker 2: GAN is so vital. Without enough functional gigaxonin, these neurofilaments
- 19:14Speaker 2: accumulate and become disorganized, disrupting axonal function and causing the
- 19:20Speaker 2: axons to balloon in size, producing the giant appearance seen
- 19:24Speaker 2: under the microscope. This accumulation of neurofilaments sounds like a
- 19:29Speaker 2: silent army march inside the axon, taking away its ability
- 19:33Speaker 2: to transmit important messages.
- 19:35Speaker 1: Right. And this is why there are still so many
- 19:37Speaker 1: unanswered questions. For example, what are the exact functional requirements
- 19:42Speaker 1: of gigasonin for axonal health? How can we quantify these requirements?
- 19:47Speaker 1: It's like having a recipe without the complete list of ingredients.
- 19:51Speaker 2: Precisely. We also need to understand the mechanism of action.
- 19:56Speaker 2: How does gigaxonin mediate the clearance of damaged neurofilaments, and
- 20:00Speaker 2: what are the pathways involved? It's like peeling back the
- 20:03Speaker 2: layers of a delicate onion to understand the intricate interactions
- 20:07Speaker 2: at play. Exactly.
- 20:09Speaker 1: Which brings up an interesting contradiction. We know there is
- 20:12Speaker 1: a lack of definitive cures, but there are still so
- 20:16Speaker 1: many supportive therapies that significantly improve quality of life. How
- 20:20Speaker 1: do we reconcile the idea that we have effective supportive
- 20:23Speaker 1: measures with the need for transformative therapies?
- 20:27Speaker 2: That's a key point, Rachel. The current approach is highly functional,
- 20:31Speaker 2: but it doesn't address the root cause. The unsolved question
- 20:35Speaker 2: of how to slow or reverse neurofilament accumulation is critical.
- 20:40Speaker 2: We need more detailed studies to see if early intervention
- 20:43Speaker 2: and new therapies can make a difference.
- 20:45Speaker 1: And what about the future? The future of GAN research
- 20:49Speaker 1: is promising with the potential for gene therapy and regenerative medicine.
- 20:54Speaker 1: We have talked about the roles of geneticists, neurologists, and others,
- 20:59Speaker 1: but these advanced therapies seem like they could be groundbreaking. However,
- 21:04Speaker 1: the challenge is integrating them into clinical practice, and validating
- 21:08Speaker 1: their effectiveness through robust trials.
- 21:10Speaker 2: Yes, exactly. The path ahead is clear. We need a
- 21:14Speaker 2: multidisciplinary approach that includes rigorous science, compassionate care, and patient advocacy.
- 21:20Speaker 2: The future is hopeful, but the journey to a cure
- 21:23Speaker 2: or more effective treatments is a marathon, not a sprint.
- 21:26Speaker 1: That's a great insight, Thomas. As we close, let's remind
- 21:30Speaker 1: our listeners of the importance of research both in understanding
- 21:33Speaker 1: the disease and in developing new therapies. With each step forward,
- 21:39Speaker 1: we bring the hope of a better, healthier future closer
- 21:42Speaker 1: to reality. That brings us to the end of today's episode.
- 21:46Speaker 1: Thank you so much for spending part of your day
- 21:47Speaker 1: with me. If you found this episode's tips helpful and
- 21:50Speaker 1: want to make sure you don't miss the next conversation,
- 21:53Speaker 1: please take a quick second to hit that subscribe or
- 21:55Speaker 1: follow button on whatever platform you are listening on. It's
- 21:59Speaker 1: a completely free way to support the show and helps
- 22:01Speaker 1: more people find us. This podcast is independently produced. So
- 22:05Speaker 1: if you are ever in a position where you would
- 22:07Speaker 1: like to help keep it running, we do accept small donations.
- 22:10Speaker 1: You can find a link right in the episode description
- 22:13Speaker 1: below to buy us a coffee or contribute what you can.
- 22:16Speaker 1: Every bit genuinely helps. Take care of yourself, stay balanced,
- 22:21Speaker 1: and we will talk again soon.